Reports
Sale
Global Cancer Vaccines Market Size, Share, Growth, Analysis: By Technology: Recombinant Cancer Vaccines, Whole-Cell Cancer Vaccines, Viral Vector and DNA Cancer Vaccines, Other Technologies; By Vaccine Type: Preventive Vaccine, Therapeutic Vaccine; By Application; Regional Analysis; Supplier Landscape; 2024-2032
Global Cancer Vaccines Market Outlook
The global cancer vaccines market size was valued at USD 8 billion in 2023, driven by the increasing initiatives by pharma giants to develop the most effective cancer vaccine. The market size is anticipated to grow at a CAGR of 11.8% during the forecast period of 2024-2032 to achieve a value of USD 21.8 billion by 2032.
Global Cancer Vaccines Market Overview
The market is propelled by the researchers putting their maximum efforts into discovering innovative combinations and developing effective cancer vaccines for several types of cancers. The cancer vaccines market demand is driven by the increasing prevalence of cancer cases globally. In 2023, around 20 million new cases of cancer were diagnosed and nearly 10 million deaths were reported across the world. The cancer burden is poised to increase by approximately 60% over the next two decades, further straining health systems, people, and communities. The predicted global burden will increase to about 30 million new cancer cases by 2040, with high incidence in low- and middle-income countries. As a result, industry leaders are coming together to collaborate, perform clinical trials, and develop cancer vaccine candidates.
Rising Adoption of Innovative Alternatives to Offer Precise Treatment
In August 2023, the National Health Service (NHS) England, United Kingdom’s publicly funded healthcare system rolled out an anti-cancer jab that can cut down treatment time for some by three-quarters. Atezolizumab (Tencentriq®), an immunotherapy drug has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and takes around 7 minutes to administer intravenously, which is significantly lesser than the conventional time span.
The release of this injection is a piece of good news for both the patients and healthcare providers as it facilitates oncologists to provide faster treatment to patients and deliver it conveniently. This approach will likely contribute to increased awareness among patients and offer notable cancer vaccines market growth in the forecast period. The rapid adaptation of innovation by the NHS indicates the commitment to improve the efficiency of health services.
Strategic Collaborations between Market Players
In October 2023, BioNTech SE revealed that Autogene cevumeran (also known as BNT122, RO7198457), a therapeutic individualized cancer vaccine candidate for pancreatic ductal adenocarcinoma (PDAC) treatment was moved to Phase 2 trials after showing promising results in the Phase 1 clinical trials. In the Phase 2 trial, the efficacy is expected to be evaluated in 260 patients, in combination with anti-PD-L1 immune checkpoint inhibitor atezolizumab and chemotherapy. The combination treatment will be tested against the current standard-of-care chemotherapy (mFOLFIRINOX).
The candidate is being jointly developed by BioNTech and Genentech (a member of the Roche Group) and is based on mRNA-based individualized neoantigen-specific immunotherapy (iNeST) platform. The alliance of prominent companies to devise improved and personalized solutions is a major market trend poised to impact the cancer vaccines market share positively in the forecast period.
Global Cancer Vaccines Market Segmentation
Market Breakup by Technology
- Recombinant Cancer Vaccines
- Whole-Cell Cancer Vaccines
- Viral Vector and DNA Cancer Vaccines
- Other Technologies
Market Breakup by Vaccine Type
- Preventive Vaccine
- Therapeutic Vaccine
Market Breakup by Application
- Prostate Cancer
- Cervical Cancer
- Melanoma
- Bladder Cancer
- Other Applications
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Cancer Vaccines Market Regional Analysis
Geographically, North America is expected to dominate the market during the forecast period. In 2023, the region reported 609,280 cancer related deaths. According to the National Cancer Institute, an estimated 2 million people are expected to be diagnosed with cancer in the United States in 2024. By 2040, the number of people expected to be diagnosed with cancer will increase by 57%, and approximately affect 6.23 million people. As a result, there has been significant emphasis on developing effective solutions for the prevention of cancer associated mortalities.
Europe holds a notable cancer vaccines market share, owing to the presence of prominent academic and research institutions along with an extensive budget to promote research activities. The increasing collaborations between healthcare companies and academic institutions is expected to drive significant market growth in the region. The Asia-Pacific region is witnessing growth, which can be attributed to rising integration of modern technologies into the medical ecosystem. The increasing efforts by the governments of emerging economies to improve the infrastructure is another notable market trend in the region.
Global Cancer Vaccines Market: Competitor Landscape
In February 2023, Moderna, Inc. and Merck announced that the FDA granted a breakthrough therapy designation to mRNA-4157/V940 in combination with pembrolizumab (Keytruda) for the adjuvant treatment of patients with high-risk melanoma following complete resection. The grant was based on the positive results from the phase 2b KEYNOTE-942 trial (NCT03897881). mRNA-4157/V940 is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine made of a single synthetic mRNA coding for up to 34 neoantigens. It works by instigating a natural immune response and generating specific T cell responses.
The key features of the cancer vaccines market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Dendreon Pharmaceuticals LLC
- Bristol Myers Squibb Company
- AstraZeneca
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Sanofi
- Pfizer Inc.
- Gilead Sciences, Inc.
- Inovio Pharmaceuticals
- Bavarian Nordic
- CureVac SE
- Takeda Pharmaceutical Company Limited
- Cascadian Therapeutics
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Technology |
|
| Breakup by Vaccine Type |
|
| Breakup by Application |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Cancer Vaccines Market Overview
3.1 Global Cancer Vaccines Market Historical Value (2017-2023)
3.2 Global Cancer Vaccines Market Forecast Value (2024-2032)
4 Global Cancer Vaccines Market Landscape*
4.1 Global Cancer Vaccines: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Cancer Vaccines: Product Landscape
4.2.1 Analysis by Products
4.2.2 Analysis by Application
5 Global Cancer Vaccines Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Cancer Vaccines Market Segmentation (2017-2032)
6.1 Global Cancer Vaccines Market by Technology
6.1.1 Market Overview
6.1.2 Recombinant Cancer Vaccines
6.1.3 Whole-Cell Cancer Vaccines
6.1.4 Viral Vector and DNA Cancer Vaccines
6.1.5 Other Technologies
6.2 Global Cancer Vaccines Market by Vaccine Type
6.2.1 Market Overview
6.2.2 Preventive Vaccine
6.2.3 Therapeutic Vaccine
6.3 Global Cancer Vaccines Market by Application
6.3.1 Market Overview
6.3.2 Prostate Cancer
6.3.3 Cervical Cancer
6.3.4 Melanoma Bladder Cancer
6.3.5 Other Applications
6.4 Global Cancer Vaccines Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Cancer Vaccines Market (2017-2032)
7.1 North America Cancer Vaccines Market (2017-2032) by Technology
7.1.1 Market Overview
7.1.2 Recombinant Cancer Vaccines
7.1.3 Whole-Cell Cancer Vaccines
7.1.4 Viral Vector and DNA Cancer Vaccines
7.1.5 Other Technologies
7.2 North America Cancer Vaccines Market (2017-2032) by Vaccine Type
7.2.1 Market Overview
7.2.2 Preventive Vaccine
7.2.3 Therapeutic Vaccine
7.3 North America Cancer Vaccines Market (2017-2032) by Country
7.3.1 United States of America
7.3.2 Canada
8 Europe Vaccines Market (2017-2032)
8.1 Europe Cancer Vaccines Market (2017-2032) by Technology
8.1.1 Market Overview
8.1.2 Recombinant Cancer Vaccines
8.1.3 Whole-Cell Cancer Vaccines
8.1.4 Viral Vector and DNA Cancer Vaccines
8.1.5 Other Technologies
8.2 Europe Cancer Vaccines Market (2017-2032) by Vaccine Type
8.2.1 Market Overview
8.2.2 Preventive Vaccine
8.2.3 Therapeutic Vaccine
8.3 Europe Cancer Vaccines Market (2017-2032) by Country
8.3.1 United Kingdom
8.3.2 Germany
8.3.3 France
8.3.4 Italy
8.3.5 Others
9 Asia Pacific Cancer Vaccines Market (2017-2032)
9.1 Asia Pacific Cancer Vaccines Market (2017-2032) by Technology
9.1.1 Market Overview
9.1.2 Recombinant Cancer Vaccines
9.1.3 Whole-Cell Cancer Vaccines
9.1.4 Viral Vector and DNA Cancer Vaccines
9.1.5 Other Technologies
9.2 Asia Pacific Cancer Vaccines Market (2017-2032) by Vaccine Type
9.2.1 Market Overview
9.2.2 Preventive Vaccine
9.2.3 Therapeutic Vaccine
9.3 Asia Pacific Cancer Vaccines Market (2017-2032) by Country
9.3.1 China
9.3.2 Japan
9.3.3 India
9.3.4 ASEAN
9.3.5 Australia
9.3.6 Others
10 Latin America Cancer Vaccines Market (2017-2032)
10.1 Latin America Cancer Vaccines Market (2017-2032) by Technology
10.1.1 Market Overview
10.1.2 Recombinant Cancer Vaccines
10.1.3 Whole-Cell Cancer Vaccines
10.1.4 Viral Vector and DNA Cancer Vaccines
10.1.5 Other Technologies
10.2 Latin America Cancer Vaccines Market (2017-2032) by Vaccine Type
10.2.1 Market Overview
10.2.2 Preventive Vaccine
10.2.3 Therapeutic Vaccine
10.3 Latin America Cancer Vaccines Market (2017-2032) by Country
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Mexico
10.3.4 Others
11 Middle East and Africa Cancer Vaccines Market (2017-2032)
11.1 Middle East and Africa Cancer Vaccines Market (2017-2032) by Technology
11.1.1 Market Overview
11.1.2 Recombinant Cancer Vaccines
11.1.3 Whole-Cell Cancer Vaccines
11.1.4 Viral Vector and DNA Cancer Vaccines
11.1.5 Other Technologies
11.2 Middle East and Africa Cancer Vaccines Market (2017-2032) by Vaccine Type
11.2.1 Market Overview
11.2.2 Preventive Vaccine
11.2.3 Therapeutic Vaccine
11.3 Middle East and Africa Cancer Vaccines Market (2017-2032) by Country
11.3.1 Saudi Arabia
11.3.2 United Arab Emirates
11.3.3 Nigeria
11.3.4 South Africa
11.3.5 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication Year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Partnership and Collaborations Analysis
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Partnership
17.3 Analysis by Leading Players
17.4 Analysis by Geography
18 Supplier Landscape
18.1 Merck & Co., Inc.
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 GlaxoSmithKline plc.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Dendreon Pharmaceuticals LLC
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Bristol Myers Squibb Company
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 AstraZeneca
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 F. Hoffmann-La Roche Ltd.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Novartis AG
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Sanofi
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 Pfizer Inc.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Gilead Sciences, Inc.
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 Inovio Pharmaceuticals
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12 Bavarian Nordic
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 CureVac SE
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
18.14 Takeda Pharmaceutical Company Limited
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.14.5 Certifications
18.15 Cascadian Therapeutics
18.15.1 Financial Analysis
18.15.2 Product Portfolio
18.15.3 Demographic Reach and Achievements
18.15.4 Mergers and Acquisitions
18.15.5 Certifications
List not exhaustive
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market attained a value of about USD 8 billion in 2023 driven by the increasing incidence of cancer across the globe.
The market is anticipated to grow at a CAGR of 11.8% during the forecast period of 2024-2032 and is likely to reach a market value of USD 21.8 billion by 2032.
The increasing awareness among people about personalized cancer vaccines, increasing incidence research activities, clinical trials, vaccine releases, and FDA approvals are driving market demand.
Pharmaceutical companies taking numerous initiatives to collaborating and develop the most effective cancer vaccines is a major market trend. In October 2023, BioNTech SE revealed that Autogene cevumeran (also known as BNT122, RO7198457), a therapeutic individualized cancer vaccine candidate for pancreatic ductal adenocarcinoma (PDAC) treatment developed by a partnership of BioNTech and Genentech was moved to Phase 2 trials after showing promising results in the Phase 1 clinical trials.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America is currently leading the global market.
The technologies include are recombinant cancer vaccines, whole-cell cancer vaccines, viral vector and DNA cancer vaccines, and other technologies.
The common cancer vaccine types include preventive vaccines and therapeutic vaccines.
The common application areas include prostate cancer, cervical cancer, among others.
Key players involved in the market are Merck & Co., Inc., GlaxoSmithKline plc., Dendreon Pharmaceuticals LLC, Bristol Myers Squibb Company, AstraZeneca, F. Hoffmann-La Roche Ltd., Novartis AG, Sanofi, Pfizer Inc., Gilead Sciences, Inc., Inovio Pharmaceuticals, Bavarian Nordic, CureVac SE, Takeda Pharmaceutical Company Limited and Cascadian Therapeutics.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER